Heron up 3% after Ad Com thumbs down on Pacira Pharma's Exparel

|About: Heron Therapeutics, Inc. (HRTX)|By:, SA News Editor

Heron Therapeutics (HRTX +3.2%) is up, albeit on below-average volume, after a negative FDA advisory committee vote on Pacira Pharmaceuticals' anesthetic drug EXPAREL (bupivacaine liposomal injectable solution).

Heron also has a local anesthetic candidate, HTX-011, a combination of bupivacaine and meloxicam. It plans to file a U.S. marketing application this year.

Previously: Heron Therapeutics' pain candidate HTX-011 shows positive effect in mid-stage studies; shares down 8% after hours on soft Sustol guidance (Jan. 4, 2017)

Subscribe for full text news in your inbox